Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients

This trial aimed to assess the activity of weekly docetaxel concurrent with radiotherapy plus three year androgen deprivation in patients with high-risk localized prostate cancer. No statistically significant differences for 5-year biochemical RFS, PFS and OS has been observed when 9 weekly docetaxel cycles were added to conventional treatment. Concurrent weekly docetaxel can be administered safely with standard doses of radiotherapy without a significant increase in the toxicity profile.

https://ift.tt/2pQZ4S7